This information was published on 2024-08-20T15:57:45 for IP Right Filed Published.
| Field | Value |
| (210) | 2475598 |
| (220) |
20 Aug 2024
|
| (300) |
US, 05 Apr 2024, 98/486,061
|
| (511) (510) |
Class 5
Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, central and/or peripheral neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders Class 42 Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology |
| (540) | DEL-DESIRAN |
| (550) | Word |
| (730) |
Avidity Biosciences, Inc.
|
| (750) |
Davies Collison Cave Pty Ltd
|
Find out more about publications on the About page.